Translational Medicine
Open Access
ISSN: 2161-1025
ISSN: 2161-1025
D.V. Ivanov
Posters: Transl Med
In Russia multi-drug resistant enterobacterial species and non-fermenters are important cause of infections in hospitalized patients. The aim of the large-scale study was the analysis of antimicrobial therapy administrations for nosocomial infections due to beta-lactams resistant gram-negative bacteria to define more effective therapy regimens. The study was conducted over 5 years in 29 regional, municipal hospitals in Russia. 900 beta-lactams resistant gram-negative bacterial strains were recovered from 770 patients with community-acquired pneumonia, nosocomial sepsis, surgical and urinary tract infections. Analysis of antibacterial drugs usage in treatment of nosocomial infections, induced by beta-lactams resistant gram-negative bacteria, showed that most often cefotaxime, ceftriaxone and amikacin are prescribed. From 86 to 100% isolated strains have demonstrated a great level to III generation cefalosporines, II-III generations aminoglycosides, and ciprofloxacin. Typical agents in a case of different diseases were following: K. pneumoniae ss. pneumonia, E. coli, P. mirabilis, E. cloacae, P. aeruginosa, and A. baumannii. PCR analysis of bacterial strains under study has shown the presence Extended Spectrum Beta-Lactamase genes: TEM, SHV, CTX-M. Most of them carry genes in different combinations: E. coli � TEM + CTX-M-1, K. pneumoniae ss. pneumonia � TEM + SHV + CTX-M-1 and SHV + CTX-M-1, E. cloacae � TEM + SHV, P. mirabilis � TEM + CTX-M-1 are most frequent. Retrospective analysis of empiric antimicrobial therapy administrations for nosocomial infections has proved the importance of control to their potential pathogens.
Dmitry V. Ivanov has completed his PhD at the age of 26 years from Yaroslavl Medical State Academy, MD at the age of 36 years from Federal Service on Surveillance in Healthcare and Social Development and postdoctoral studies from Russian Medical Academy Postgraduate Training. He is head of clinical trials department at SPP PHARMACLON LTD, Moscow, Russia. He has published more than 20 papers in peer-reviewed journals. His early main research interest was on the human biotops microflora. In 2003, he was appointed senior researcher at the National Research Center of Antibiotics, Russia and began to investigate nosocomial bacterial infections.